- Home
- HRMY vs GRDN Comparison
HRMY vs GRDN Comparison
Compare HRMY & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- GRDN
- Stock Information
- Founded
- HRMY 2017
- GRDN 2004
- Country
- HRMY United States
- GRDN United States
- Employees
- HRMY N/A
- GRDN N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- HRMY Health Care
- GRDN Consumer Staples
- Exchange
- HRMY Nasdaq
- GRDN Nasdaq
- Market Cap
- HRMY 2.1B
- GRDN 1.8B
- IPO Year
- HRMY 2020
- GRDN 2024
- Fundamental
- Price
- HRMY $32.29
- GRDN $27.24
- Analyst Decision
- HRMY Strong Buy
- GRDN Strong Buy
- Analyst Count
- HRMY 9
- GRDN 2
- Target Price
- HRMY $55.33
- GRDN $24.50
- AVG Volume (30 Days)
- HRMY 678.1K
- GRDN 345.7K
- Earning Date
- HRMY 10-28-2025
- GRDN 11-11-2025
- Dividend Yield
- HRMY N/A
- GRDN N/A
- EPS Growth
- HRMY 58.41
- GRDN N/A
- EPS
- HRMY 3.10
- GRDN N/A
- Revenue
- HRMY $772,527,000.00
- GRDN $1,326,604,000.00
- Revenue This Year
- HRMY $20.09
- GRDN $16.17
- Revenue Next Year
- HRMY $16.86
- GRDN $2.31
- P/E Ratio
- HRMY $10.42
- GRDN N/A
- Revenue Growth
- HRMY 17.74
- GRDN 18.53
- 52 Week Low
- HRMY $26.47
- GRDN $14.16
- 52 Week High
- HRMY $41.61
- GRDN $30.39
- Technical
- Relative Strength Index (RSI)
- HRMY 30.41
- GRDN 54.36
- Support Level
- HRMY $31.61
- GRDN $27.35
- Resistance Level
- HRMY $37.05
- GRDN $30.39
- Average True Range (ATR)
- HRMY 1.18
- GRDN 1.16
- MACD
- HRMY -0.59
- GRDN -0.09
- Stochastic Oscillator
- HRMY 10.19
- GRDN 40.47
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.